Emerging, clinical and molecular data unequivocally show that the presence of intratumoural heterogeneity, exemplified by focal CEACAM6 overexpression in HNSCC cells, is a major contributor to tumour drug responses and patient outcomes[17]. This evidence concerns the gene CEACAM6 and head and neck squamous cell carcinoma.